All News
FDA Panel Rejects Tanezumab for Osteoarthritis
A two day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab, a nerve growth factor inhibitor, for use in osteoarthritis (OA).
Read Article
Future Therapeutics for Rheumatoid Arthritis and Lessons Learned - RNL2021 Highlights
In case you missed it, RheumNow Live 2021 delivers what it promises: a good consistent program pack with high energy interactive learning.
Read Article
Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned
https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D
Links:
Dr. John Cush RheumNow ( View Tweet)
News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis
A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA.
https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd
Links:
Dr. John Cush RheumNow ( View Tweet)
The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease
Sponsored by Novartis Medical Affairs
Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020.
View Now: https://t.co/Kp2drDAqFv https://t.co/tjkUpxcMdT
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 coverage from @uptoTate #RheumNow https://t.co/u11ltNc2vA
Dr. John Cush RheumNow ( View Tweet)
The RheumNow podcast is up--Great Associations
Dr. Jack Cush rants on the journal reports, news and FDA actions featured last week on RheumNow.
https://t.co/gzWVbL8xMJ
Links:
Dr. John Cush RheumNow ( View Tweet)
Claims data analysis (MarketScan, Medicare, Optum) of 87,653 RA patients starting either TNF inhibitor or tofacitinib shows venous thromboembolism (VTE) is rare (<1 per 100) RA Rx with either. VTE risk was same for Tofa and TNFi (HR of 1.13 [0.77-1.65]) https://t.co/UoMQRp12vo
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 https://t.co/bZdTYFdEn4
Dr. John Cush RheumNow ( View Tweet)
News Feature: Safety of Paternal DMARD or Biologic Use
https://t.co/9jCNJ9rHYF https://t.co/SIRPcPQxyB
Links:
Dr. John Cush RheumNow ( View Tweet)
Retrospective study of 162 ANCA-Assoc Vasculitis patients (63% GPA, 37% MPA) - risk of serious infx was 7.5 per 100Pt-Yrs & was higher with cyclophosphamide that RTX induction. Risks for SIE:plasmapheresis dialysis & high BVAS in 1st year https://t.co/kAlz9aGQup
Links:
Dr. John Cush RheumNow ( View Tweet)
Dr. Fleischmann vs. Dr. Matsumoto: get rid of MTX vs. get rid of biologic in RA remission. Both argue on sustained remission, risk for anti-drug antibodies, longterm safety. Dr. Buch’s perfect answer… “it depends on patient’s preference, cost.” #RNL2021 https://t.co/FBf2uoDx0B
k dao KDAO2011 ( View Tweet)
Why Pain Consults present Not Taking Pain Meds
https://t.co/75YO027Oh6 https://t.co/rir90gM7qv
Links:
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Gr Rounds - Dr Saag
Rules around genetic testing for HLA-B5801 @UTSWIMchief @KenSaag https://t.co/QCpKv0J2s2
Dr. John Cush RheumNow ( View Tweet)
UTSW Rheum Gran Rounds - Dr. Ken Saag, Anakinra vs IA steroids @UTSWIMchief @KenSaag https://t.co/M2UCbyuJpb
Dr. John Cush RheumNow ( View Tweet)
Dr. Ken Saag giving Rheum Grand Rounds at UT Southwestern. Data showing lower dose colchicine is safer than higher dose in acute gout @UTSWIMchief @KenSaag https://t.co/5KAn9SWlrU
Dr. John Cush RheumNow ( View Tweet)
Biologic efficacy in 147 pts w/ eosinophilic granulomatosis with polyangiitis - compares RTX (63), mepolizumab (51) or omalizumab (31). Remission/partial rates were better in RTX (49%/24%) and MEPO (78%, 10%) vs OMA (15%/33%) https://t.co/ZsCFVnasIJ
Links:
Dr. John Cush RheumNow ( View Tweet)
#RNL2021 https://t.co/8Cs4RZhBpW
Dr. John Cush RheumNow ( View Tweet)
Uveitis is uncommonly caused drugs - especially : bisphosphonates, immune checkpoint inhibitors and antiviral drugs. https://t.co/hWO3QFcuMb
Links:
Dr. John Cush RheumNow ( View Tweet)
